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The State of Insulin m the Blood* 
THADDEUS E. PROUT 
Department of Medicine, Johns Hopkins University 
School of Medicine, Baltimore, Maryland 
In discussing the state of insulin 
in the blood, I should like to review 
briefly the regulation of insulin 
secretion and what is known about 
its manner of synthesis and release. 
Since some of the insulin in the 
blood may be in an ineffective or 
inactive state, I shall refer to active 
insulin as efjective insulin. 
METABOLITE STIMULATORS 
The stimulus acting on the pan-
creas that controls the level of 
effective insulin in the blood is 
probably related to more than one 
metabolite. For many years glucose 
was considered the only substance 
capable of insulin stimulation, but 
recently it has been shown that 
keto-acids (Mebane and Madison, 
1962) and certain amino acids such 
as leucine and arginine (Floyd et 
al., 1965; Merimee et al., 1965) 
can also stimulate insulin release. 
There is need to learn whether this 
has physiological significance be-
fore assigning it a specific role in 
the checks and balances of human 
metabolism. Intravenous studies 
using arginine will be followed by 
oral feedings of appropriate animal 
proteins to determine whether or 
not there will be an increase in the 
level of serum insulin without a 
rise in blood sugar. 
* The schema presented here is the 
result of much discussion involving 
all members of the endocrine division 
at the Johns Hopkins Hospital. Dr. 
Kenneth Zierler, Dr. David Rabino-
witz, .and Dr. Thomas Merimee are 
especially cited in the formulation of 
· these concepts. 
SENSING-RELEASING 
MECHANISMS 
The manner in which glucose or 
other metabolites bring about the 
secretion of insulin is unknown. It 
is reasonable to postulate that a 
sensing device must be present that 
recognizes the amount of the spe-
cific stimulator present and in-
forms the pancreas that insulin is 
needed. This immediately raises the 
possibility that a pathologic state 
could exist wherein a faulty sensing 
device would fail to inform the 
pancreas of the need, and insulin 
would not be secreted despite the 
presence of normal quantities of 
insulin in the pancreas. Studies with 
the sulfonylurea drugs may per-
haps be interpreted as bearing on 
this question. It is clear that insulin 
can exist within the islet cells quite 
unaware of the hyperglycemic blood 
flowing past and that sulfonylurea 
drugs can bring about the release 
of this insulin. These drugs may 
activate a sensing device. It is 
equally possible that they may ac-
tivate a releasing mechanism for 
we cannot separate these two postu-
lated functions clinically. In indi-
viduals with adequate pancreatic 
stores of insulin that are not re-
sponsive to elevated levels of glu-
cose, the sulfonylurea drugs bring 
about a more normal response to 
the stimuli. There is increasing evi-
dence that there is carbohydrate 
intolerance that advances with age 
(Andres, 1966, in press) and again 
it seems likely that this relative in-
sensitivity comes about through a 
failure either of the sensing device 
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or releasing mechanism. Perhaps 
other conditions which alter insulin 
release, such as the glucose intoler-
ance following fasting, may relate 
to these mechanisms. 
SYNTHESIS AND STORAGE 
Although we can say little about 
the mechanisms of release of in-
sulin, we are indebted to the beau-
tiful studies by Lacy ( 1961) with 
the electron microscope for an ex-
position of the migration of the 
insulin granule across the beta-cell 
to the cell surface. On reaching the 
cell surface, the envelope of the 
beta granule appears to coalesce 
with the surface membrane where 
upon the beta granule is discharged 
into the extracellular space. At this 
point, unfortunately, the resolution 
of the electron microscope does 
not allow further physical view of 
the discharged granule. After dis-
charge of the previously stored 
insulin, empty sacks are again seen 
in the beta cell; these are fre-
quently surrounded in part by a 
protein believed to be ribonuclear 
protein. The ribonuclear protein 
granules clustered about the sack 
slowly disappear as the amorphous 
material fills the empty sack, and 
it is easy to presume that we have 
witnessed the synthesis of insulin 
on a template. The amorphous ma-
terial in the sack is next seen to 
condense into a storage form that 
is typical of the beta granules pre-
viously discharged. The discharge 
of these granules in response to 
known stimuli such as glucose and 
sulfonylurea drugs adds further to 
the circumstantial evidence that we 
are in fact witnessing the synthesis 
and release of insulin. 
Randle and his associates (see 
Coore and Randle, 1964) have 
been able to show that insulin can 
be released from pancreatic slices 
in vitro by the addition of glucose 
to the medium. In this system, 
epinephrine inhibits the release of 
insulin by both glucose and the sul-
fonylureas. Perhaps the most im-
portant observation has been that 
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he has been able to prevent the re-
lease of insulin from the pancreas 
by the addition of manoheptulose 
when glucose is added to the me-
dium, but manoheptulose does not 
prevent the release of insulin under 
the stimulus of the sulfonylureas. 
This is the first time that anyone 
has been able to separate the re-
lease mechanisms associated with 
glucose from those related to the 
sulfonylureas and parenthetically 
this suggests that the release mech-
anism rather than the sensing device 
is the site of action of the sulfony-
lureas in human subjects. 
CIRCULATING INSULIN 
In considering the state of in-
sulin in the blood, we must deal 
with certain direct questions: What 
is its form? How is it transported? 
And what is the material being 
measured which we call "insulin?" 
These are fundamental questions, 
but our answers must be incom-
plete. 
From the work of Sanger (1960) 
we have the precise structure of the 
insulin molecule, and the molecular 
weight is known to be approxi-
mately 6,000. It has not been pos-
sible to be certain of the form 
taken by circulating insulin. It 
probably circulates as a double 
molecule or dimer with a molecu-
lar weight of 12,000, but it may 
circulate in aggregates of three or 
four molecules (Prout, 1963). 
There is some evidence that the 
insulin may be transported in the 
blood attached to a carrier protein, 
but this cannot be definitely proven 
at this time. 
Insulin is measured in biologic 
fluids on the basis of its biologic 
effect or its immunologic properties. 
In general, there are two types of 
biological assay, one measuring the 
effect of glucose uptake or glycogen 
deposition in a rat hemi-diaphragm 
and the other measuring the incor-
poration of C" from labelled glu-
cose into glycogen or CO. by the 
rat epididymal fat pad. Both of 
these tests measure a net biologi-
cal effect which may be altered as 
a result of several modifying fac-
tors either potentiators or inhibi-
tors. For this reason, the activity 
thus measured is referred to as the 
"insulin-like activity"' or ILA. The 
immunoassay of Berson and Yalow 
( 1960) identifies immunologically 
active insulin quite specifically and 
with considerable sensitivity; it is, 
of course, able to tell us nothing 
about the biological activity of the 
thing that is measured. About these 
two types of assay have grown up 
two schools of thought which di-
vide the investigators interested in 
this field . 
Faced with this dilemma, it is of 
some comfort to consider the num-
ber of ways in which the ILA as 
measured by the diaphragm and the 
immunoassay give parallel results 
(table 1). By both tests the blood 
insulin is low in the fasting sub-
jects but rises after glucose or after 
administration of the sulfonylureas. 
By both tests the blood insulin is 
high in patients with insulin secret-
ing islet cell tumors. In obese pa-
tients both assay techniques reveal 
increased insulin levels. The levels 
may be high by both assay meth-
ods in certain adult diabetes, and 
most importantly immunologically 
active insulin and ILA as tested by 
the rat hemi-diaphragms are both 
TABLE l 
Similarities in the Assay of Insulin in Whole 
Serum by the Rat Diaphragm and by the 
Immunoassay . 
l) Law insulin levels in blood of fasting pa-
tients 
2) Rise of insulin after glucose administra-
tion 
3) Rise of insulin after sulfonylurea admin-
istration 
4) High levels of insulin In hyperinsulinlsm 
5) Elevated levels of Insulin in some obese 
subjects 
6) Suppre~lon of Insulin in vitro and in 
vivo by specific Insulin antibodies 
7) Disappearance of Insulin ofter pancrea-
tec.tomy 
8) Absence of Insulin in serum of patients 
in diabetic keto-acidosis 
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suppressed by anti-insulin anti-
bodies either in vitro or in vivo. 
Finally, the insulin measured by 
either method disappears when the 
pancreas has been removed. In 
these respects both assays would 
appear to be measuring the same 
material. 
The observation that insulin-like 
activity measured by the fat pad 
was several fold that measured 
by the diaphragm or the immuno-
assay turned attention to the ques-
tion of whether or not a circulating 
form of insulin existed which had 
lost, or perhaps had never had, 
immunologic identity. By means of 
a cation exchange resin column, 
Antoniades and his associates 
( 1964) separated a form of insulin-
like activity that could be measured 
initially by the fat pad but not by 
the diaphragm or immunoassay. 
This was called "bound" insulin as 
opposed to the "free" form. Others 
have found insulin-like activity that 
is "atypical" (Samaan et al., 1963) 
or "non-suppressible" (Froesch et 
al., 1963) because the activity un-
like that of crystalline insulin is 
not inhibited by anti-insulin anti-
sera added to the test medium. 'Ve 
can conveniently consider together 
these various types of "bound," 
"complexed," "non-suppressible," 
or "typical" insulins and contrast 
them to insulin that is measurable 
by the other methods (table 2). 
One difficult problem confront-
ing the proponents of atypical in-
sulin in that some "atypical" insulin 
seems to persist in the blood for 
considerable periods of time after 
pancreatectomy (Goldberg and 
Egdahl, 1961). Before attempting 
to give clinical relevance to ILA 
of the "atypical" type, a second 
observation requires physiologic 
explanation. We are asked, for 
example, to believe that ILA meas-
ured only by the fat pad is circulat-
ing in excess quantities in patients 
with decompensated diabetes in 
whom the principle evidence of 
decompensation is failure of insulin 
to act normally upon fat synthesis 
(Steinke et al., 1961). These criti-
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TABLE 2 
Differences Between "Typical" and "Atypical" insulin 
"Typical" "Atypical" 
Assay Measured by diaphragm Measured by fat-pad 
fat-pad and immunoassay 
Effect of Inhibited Not inhibited 
antiserum 
Effect of pan- Disappears Remains 
createctomy 
Origin Pancreas Unknown 
K eto-aci dos is Absent Present in large 
quantity 
Other unresolved Biologic activity of in- Cannot be converted 
questions sulin measured immuno- reproducibly to 
logically is not known typical form 
TABLE 3 
The Feed-back Mechanism of Insulin Synthesis and Release 
Metabolite 
stimulator 
l 
Sensing-releasing 
device 
Pancreatic synthesis 
and storage 
Cellular response 
Metabolite utilization 
t 
Insulin-cell receptor 
linkage 
t 
Insulin in biologic 
fluids 
cisms have lead many to deny that 
"atypical" insulin has any real rela-
tionship to true pancreatic insulin. 
Despite these difficulties, it is theo-
retically possible that some form 
of insulin may exist which is differ-
ent from the insulin measured im-
munologically and by its biologic 
effects on muscle and further study 
of the problem will be necessary. 
A FEED-BACK MECHANISM 
We can now picture the glucose 
insulin regulating mechanism as a 
feed-back system (table 3). A met-
abolic stimulator, usually glucose, 
is measured by a sensing device 
which tells the pancreatic cell to 
release and re-synthesize insulin in 
relation to metabolic need. After 
circulating insulin has arrived in the 
blood, it is picked up by a specific 
cell receptor and initiates a cellular 
response. The cellular response not 
only serves a metabolic need but 
also removes from the blood some 
of the metabolic stimulator that 
initiated the cycle. As a result of 
the fall in the metabolite, no fur-
ther stimulation for insulin release 
is given, and the feed-back mecha-
nism is satisfied. Various other fac-
tors can presumably inhibit or po-
tentiate the different steps of this 
process. 
In this framework the diabetes 
with which we have been most 
familiar in the past is associated 
with failure of insulin release from 
the pancreas. This is most typically 
exemplified as the pancreatic ex-
haustion of juvenile diabetes. It is 
also true of the pancreas that has 
been destroyed by pancreatitis, 
hemochromatosis, or removed by 
the surgeon's knife. It may be seen 
where pancreatic exhaustion results 
from metabolic stresses such as 
hyperthyroidism, multiple pregnan-
cies, or long-standing obesity. In all 
cases the pancreas is no longer able 
to respond to demand, and clinical 
diabetes is seen. In true pancreatic 
exhaustion the sulfonylureas are, of 
course, ineffective. 
We should also note that a state 
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of functional low insulin output 
exists where there is either dulling 
of the sensing device or interfer-
ence with insulin release; either 
of these mechanisms impairs the 
ability of the pancreas to deliver 
insulin on demand. In these in-
stances, the sulfonylureas release 
insulin. Epinephrines and the thi-
azides inhibit release of insulin. 
The new concept that must be 
brought into this scheme is the 
clinical situation in which metabolic 
abnormalities of the type seen in 
diabetes are present in spite of 
high circulating levels of insulin. 
A state of impaired carbohydrate 
intolerance in association with a 
high level of plasma insulin can be 
understood if the insulin present 
is ineffective. It is also possible to 
recognize the clinical syndrome in 
which normal high levels of insulin 
compete with antagonists such as 
growth hormone, acromegaly, or 
adrenal steroids. A similar though 
less well defined impairment of in-
sulin is seen in association with 
obesity. Here again we may see 
impaired carbohydrate tolerance in 
the presence of high circulating 
levels of insulin (Karam et al., 
1963). In this state it appears 
likely that the impairment to in-
sulin function is located primarily 
at the level of cellular response. 
The same may be true in carbo-
hydrate induced hypertriglyceri-
demia, a condition closely allied to 
diabetes but not necessarily true 
diabetes. There is some evidence 
that the lipoatrophic form of dia-
betes may be characterized by high 
levels of circulating insulin that are 
rendered ineffective by an insulin 
antagonist (Louis et al., 1965). 
"Prediabetes" may take one of 
two forms. It may be a state in 
which high levels of insulin are put 
out to overcome peripheral impair-
ment or circulating antagonists but 
in which carbohydrate intolerance 
cannot be demonstrated by ordi-
nary techniques. This state is readily 
understood within the present 
framework. "Prediabetes" may also 
be present in a patient who shows 
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evidence of the "complications" of 
diabetes before carbohydrate toler-
ance is lost. There is some evidence 
that different tissues react to differ-
ent levels of insulin and by pre-
sumption that levels of insulin ade-
quate for the metabolism of some 
tissue would be ineffective for 
others. This may well be the rea-
son why it is possible to see de-
generative complications in the 
retina that is typical of diabetic 
retinopathy in some patients who 
have no carbohydrate intolerance. 
The same may be true of patients 
who develop vascular disease in 
the absence of alterations in carbo-
hydrate utilization. Perhaps the 
future study will allow us to dem-
onstrate that tissue sensitivity in 
such patients is the cause of the 
degenerative complications. There 
is abundant evidence that compli-
cations may be seen in the absence 
of carbohydrate impairment, and 
we can no longer accept the fre-
quently stated belief that control of 
carbohydrate metabolism in dia-
betes will prevent all other forms 
of the "complications." 
Much of the theme presented 
here can be verified, but much of 
it still remains speculative. It is 
probably possible to place all vari-
ants of the diabetic state some-
where within this cycle so that dia-
betes will eventually become better 
understood as a complex metabolic 
disorder involving all tissues and 
all metabolites rather than the 
simple derangement of carbohy-
drate utilization. 
SUMMARY 
Diabetes mellitus has been re-
viewed as a group of conditions 
with impaired function of one or 
more portions of a feed-back sys-
tem involving the release and utili-
zation of insulin. It is hoped that 
this may form a useful scheme by 
which we can study and understand 
a number of complex metabolic 
states which we must still collec-
tively refer to as diabetes mellitus. 
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